Editors' ChoiceImmunology

Papers of note in Science Translational Medicine 9 (389)

See allHide authors and affiliations

Sci. Signal.  16 May 2017:
Vol. 10, Issue 479, eaan6297
DOI: 10.1126/scisignal.aan6297

This week’s articles highlight how tumor-associated macrophages limit the efficacy of PD-1–targeted checkpoint therapy and show that an anti-inflammatory drug may be used to treat lymphedema.

CANCER IMMUNOTHERAPY

Tug-of-war for anti–PD-1

Arlauckas et al. found that tumor-associated macrophages remove PD-1–blocking antibodies from T cells, thus inactivating them; however, this process may be overcome by inhibiting Fcγ receptors.

INFLAMMATION

Relieving lymphedema

Tian et al. showed that surgery- or chemotherapy-induced lymphedema might be prevented or treated with the anti-inflammatory drug ketoprofen, which inhibits the production of the 5-lipoxygenase metabolite leukotriene B4 (LTB4) and consequently may activate Notch signaling.

Highlighted Articles

View Abstract

Navigate This Article